乙型肝炎表面抗原血清清除与慢性乙型肝炎病毒感染患者长期临床结局的关联:系统评价与荟萃分析
该系统评价与荟萃分析纳入28项研究、188,316例慢性HBV感染患者(治疗与未治疗)及1,486,081人年随访,评估HBsAg血清清除与长期临床结局的关联。HBsAg血清清除组复合事件率为0.19/1000人年,持续阳性组为2.45/1000人年;血清清除组肝失代偿、HCC、肝移植和/或死亡及复合终点的汇总RR分别为0.28、0.30、0.22和0.31。结论认为HBsAg血清清除与患者结局改善显著相关,支持将其作为慢性HBV感染试验的主要终点。
要点
- HBsAg血清清除组复合事件率为0.19/1000人年,持续阳性组为2.45/1000人年。
- 血清清除组肝失代偿RR为0.28(95%CI 0.13-0.59;P=.001)。
- 血清清除组HCC的RR为0.30(95%CI 0.20-0.44;P<.001),肝移植和/或死亡RR为0.22(95%CI 0.13-0.39;P<.001),复合终点RR为0.31(95%CI 0.23-0.43;P<.001)。
核心结论
- 系统评价与荟萃分析发现HBsAg血清清除与患者结局改善显著相关,不同研究类型及所检查的患者亚群中结果一致,支持将HBsAg血清清除作为慢性HBV感染患者试验的主要终点。
研究设计与样本
- 系统检索PubMed、EMBASE和Cochrane Library数据库中评估HBsAg状态并报告随访期间HCC、肝失代偿、肝移植和/或全因死亡率发生率的文章。
- 共分析28项研究,纳入188,316例慢性HBV感染患者(治疗与未治疗),随访1,486,081人年;其中26项报告HCC数据,7项报告肝失代偿数据,13项报告肝移植和/或死亡数据。
- 采用随机效应模型对每个终点及复合终点分别进行率比(RR)的荟萃分析。
主要发现
- HBsAg血清清除组复合事件率为0.19/1000人年,HBsAg持续阳性组为2.45/1000人年。
- HBsAg血清清除组肝失代偿的汇总RR为0.28(95%CI 0.13-0.59;P=.001)。
- HBsAg血清清除组HCC的汇总RR为0.30(95%CI 0.20-0.44;P<.001)。
- HBsAg血清清除组肝移植和/或死亡的汇总RR为0.22(95%CI 0.13-0.39;P<.001)。
- HBsAg血清清除组复合终点的汇总RR为0.31(95%CI 0.23-0.43;P<.001);不同研究或患者特征亚组间RR估计值未见差异。
关键数值与推荐
- HBsAg血清清除组复合事件率0.19/1000人年,HBsAg持续阳性组2.45/1000人年。
- 肝失代偿:血清清除组RR 0.28(95%CI 0.13-0.59;P=.001)。
- HCC:血清清除组RR 0.30(95%CI 0.20-0.44;P<.001)。
- 肝移植和/或死亡:血清清除组RR 0.22(95%CI 0.13-0.39;P<.001)。
- 复合终点:血清清除组RR 0.31(95%CI 0.23-0.43;P<.001)。
临床怎么用
- 原文结论支持将HBsAg血清清除作为慢性HBV感染患者试验的主要终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Seroclearance of hepatitis B surface antigen (HBsAg) is the desired end point of treatment for chronic hepatitis B virus (HBV) infection, according to guidelines. We performed a systematic review and meta-analysis to evaluate the strength of the association between HBsAg seroclearance and long-term clinical outcomes. METHODS: We performed a systematic review of the PubMed, EMBASE, and Cochrane Library databases for articles that assessed HBsAg status and reported the incidence of hepatocellular carcinoma (HCC), liver decompensation, liver transplantation, and/or all-cause mortality during follow-up evaluation. We performed a meta-analysis of rate ratios (RR) using a random-effects model independently for each end point and for a composite end point. RESULTS: We analyzed data from 28 studies, comprising a total of 188,316 patients with chronic HBV infection (treated and untreated), and 1,486,081 person-years (PY) of follow-up evaluation; 26 reported data on HCC, 7 on liver decompensation, and 13 on liver transplantation and/or death. The composite event rates were 0.19/1000 PY for the HBsAg seroclearance group and 2.45/1000 PY for the HBsAg-persistent group. Pooled RRs for the HBsAg seroclearance group were 0.28 for liver decompensation (95% CI, 0.13-0.59; P = .001), 0.30 for HCC (95% CI, 0.20-0.44; P < .001), 0.22 for liver transplantation and/or death (95% CI, 0.13-0.39; P < .001), and 0.31 for the composite end point (95% CI, 0.23-0.43; P < .001). No differences in RR estimates were observed among subgroups of different study or patient characteristics. CONCLUSIONS: In a systematic review and meta-analysis, we found seroclearance of HBsAg to be associated significantly with improved patient outcomes. The results are consistent among different types of studies, in all patient subpopulations examined, and support the use of HBsAg seroclearance as a primary end point of trials of patients with chronic HBV infection.
引用
- Anderson RT, Choi HSJ, Lenz O, et al. Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2020. PMID: 32473348. doi:10.1016/j.cgh.2020.05.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。